Executive Vice President of Sales, Zynex
Search every verified Steve Fox interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a September 2024 interview, Zynex CEO Thomas Sandgaard discussed the company's growth and product pipeline. Sandgaard stated that Zynex, which he founded 28 years ago, expects to reach $200 million in revenue this year, up from $11 million seven or eight years ago, and that the company continues to grow at a double-digit percentage. He said the company has been able to buy back stock and invest tens of millions of dollars in hospital monitoring while remaining profitable and cash-flow positive. Sandgaard described the NextWave device as the company's flagship and current primary revenue generator, noting it is often prescribed by orthopedic surgeons for post-surgery pain relief and to increase blood circulation. He said the company expects long-term pain management revenues to eventually hit or exceed $800 million. Regarding hospital monitoring, Sandgaard said Zynex has four products in development, including one that he said can more accurately measure oxygen levels in patients with dark skin pigmentation, a flaw he attributed to existing devices. He said the company expects to submit an application to the FDA for that product in the fourth quarter of 2024.
“The company is 28 years old. I founded it, in a one bedroom 28 years ago. And this year, we'll see a 200 million in revenue. Just 7 or 8 years ago, we only had 11 million in revenue. So we've been growing fast. And, we continue to grow at a double digit percentage.”
“We pay very close attention to always being profitable and having a positive cash flow along the way. We've been very successful in doing so, so much that we've been able to buy back stock 1 to $80 million year over the past few years and invest tens of millions dollars in our hospital monitoring to patients so far.”
“In hospital monitoring, we have four game changing products on the way. There's no revenue in that division yet, even though one of them in particular is very close, so that we can launch it here, we expect, while the application with the FDA here late later this year in the fourth quarter and hopefully get clearance i...”
“We have a product that will be trying to gain as much market share as possible. Not only are we able to more accurately detect oxygen levels in the blood at the same way it's done today with typically a finger clip, and we will also be able to accurately detect carbon monoxide levels, reduced hemoglobin and Myoglobin v...”
Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to detail the impressive growth and cutting-edge ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Steve Fox.